Transgelin/TAGLN Antibody #40471
- WB
- IF
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 23 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunofluorescence (Frozen) | 1:100 - 1:200 |
| Immunofluorescence (Immunocytochemistry) | 1:100 - 1:200 |
Storage
Protocol
Specificity / Sensitivity
Transgelin/TAGLN Antibody recognizes endogenous levels of total Transgelin/TAGLN protein.
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly171 of human Transgelin/TAGLN protein. Antibodies are purified by peptide affinity chromatography.
Background
Transgelin (TAGLN, SM22α) is an actin-binding protein of the calponin family. It contains an amino-terminal calponin homology domain and a carboxy-terminal calponin-like module domain required for actin binding (1,2). TAGLN is a TGF-β inducible gene that is abundantly expressed in visceral and vascular smooth muscle cells, and is often used as an early marker of smooth muscle differentiation (3-5). TAGLN expression has also been shown in brain pericytes, providing use in studying the blood brain barrier (6). Altered levels of TAGLN are seen in multiple cancer types, including colorectal, breast, and prostate cancer (4).
- Assinder, S.J. et al. (2009) Int J Biochem Cell Biol 41, 482-6.
- Fu, Y. et al. (2000) J Appl Physiol (1985) 89, 1985-90.
- Hirschi, K.K. et al. (1998) J Cell Biol 141, 805-14.
- Dvorakova, M. et al. (2014) Expert Rev Proteomics 11, 149-65.
- Huang, L. et al. (2018) J Cell Mol Med 22, 6249-6261.
- Blanchard, J.W. et al. (2020) Nat Med 26, 952-963.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.